英文药名：Zeftera(ceftobiprole medocaril injection) 中文药名：头孢托罗冻干粉注射剂 生产厂家：扬森-Cilag（英国公司） 药品介绍 新类广谱抗生素Zevtera的第一个头孢托罗注射剂获批上市，用于治疗包括糖尿病脚感染在内的复杂性皮肤和皮肤软组织感染。 本品是一新颖的广谱抗生素，在检测出引起感染的确切细菌前即可作为一线治疗药使用。 头孢托罗专门设计结合于许多革兰阳性球菌类上的耐青霉素（造成细菌活性转向MRSA和耐青霉素的肺炎链球菌）靶点。头孢托罗作为单一静脉注射剂显示对其它许多常常发生在社区和医院传染的革兰阳性菌和革兰阴性菌有广谱抗菌活性。用于治疗18岁及以上的微生物可疑菌感染：复杂性皮肤和皮肤软组织感染。包括不威胁肢体的糖尿病脚感染（无同时患有阴沟肠杆菌、大肠杆菌、肺炎克雷伯杆菌、奇异变形杆菌、包括耐甲氧西林在内的金黄色葡球菌和化脓链球菌引起的骨髓炎）。 剂  型： 冻干粉注射剂; 500mg  10瓶/盒 Zeftera (Ceftobiprole Medocaril) Generic Name: ceftobiprole   Trade Name: Zevtera (EU), Zeftera (US)   UK: Launched  EU: Launched  US: None  UK launch date: May 2015  Comments May 15: Launched in the UK. 21/05/2015 09:35:20 BNF Category: Cephalosporins, carbapenems and other beta-lactams Pharmacology: Novel cephalosporin  Indication: Bacterial infections Drug Overview Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin. Upon intravenous administration, ceftobiprole medocaril is rapidly converted to the active drug, ceftobiprole, in the plasma. The drug’s mechanism of action stems from its ability to bind to different types of penicillin-binding proteins found in both Gram-negative and Gram-positive bacteria. Upon binding to such proteins, the drug exhibits its bactericidal activity through inhibiting transpeptidation, and the formation of the bacterial cell wall, leading ultimately to cell lysis and death. Zeftera demonstrated in vitro activity against a broad spectrum of bacterial pathogens, including some drug-resistant Gram-positive strains such as methicillin-resistant Staphylococcus aureus, vancomycin resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumonia, and ceftriaxone-resistant Streptococcus pneumonia.